Clinical Utility of GBA Genotyping Prior to Deep Brain Stimulation: A Narrative Review
Genes · 2026
DOI: 10.3390/genes17010069 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Valentino Rački und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Glucosylceramidase, Parkinson Disease. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Variants in the GBA gene represent the most common genetic risk factor for Parkinson’s disease and are associated with a more aggressive disease course. Deep brain stimulation is an established therapy for advanced Parkinson’s disease, yet the influence of GBA status on postoperative outcomes remains incompletely defined. This review aims to summarize the clinical relevance of GBA genotyping prior to DBS and to evaluate its potential contribution to decision-making, risk stratification, and long-term management.
Methods
A structured narrative review was conducted. The literature on sequencing methodology, variant interpretation, and postoperative outcomes in GBA-positive and GBA-negative patients was examined. Particular focus was placed on motor, cognitive, and neuropsychiatric outcomes, and on studies comparing trajectories across variant classes.
Results
Across all study designs, patients with GBA-associated Parkinson’s disease demonstrated robust motor improvement after DBS, with outcomes comparable to those in non-carriers. Cognitive and neuropsychiatric decline occurred more rapidly in GBA carriers. Recent evidence indicates that cognitive and neuropsychiatric decline is influenced more by the genetic profile than the stimulation procedure. Variant severity appears to influence postoperative trajectories. Long-read sequencing improves detection of recombinant alleles and may refine genotype–phenotype associations. Genotyping provides additional value in counseling, expectation management, and postoperative planning.
Conclusions
DBS remains an effective motor therapy for patients with GBA-associated Parkinson’s disease. Current findings indicate GBA genotyping should inform, and not limit, candidate selection. Integration of clinical, cognitive and genetic data supports more individualized management. Methodological advances in sequencing and the development of prediction models may further enhance personalized DBS planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.
- Department of Neurology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
- Department of Neurology, University Hospital Dubrava, 10000 Zagreb, Croatia.
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
- Special Hospital for Orthopedics and Rehabilitation "Martin Horvat", 52210 Rovinj, Croatia.
ORCID-Profile: Valentino Rački, Filip Ðerke, Andrej Belančić, Matija Sošić
Zitieren
APA
Rački, V., Lasić, S., Ðerke, F., Belančić, A., & Sošić, M. (2026). Clinical Utility of GBA Genotyping Prior to Deep Brain Stimulation: A Narrative Review. Genes. https://doi.org/10.3390/genes17010069
Vancouver
Rački V, Lasić S, Ðerke F, Belančić A, Sošić M. Clinical Utility of GBA Genotyping Prior to Deep Brain Stimulation: A Narrative Review. Genes. 2026. doi:10.3390/genes17010069
BibTeX
@article{Raki2026,
author = {Rački, Valentino and Lasić, Slaven and Ðerke, Filip and Belančić, Andrej and Sošić, Matija},
title = {Clinical Utility of GBA Genotyping Prior to Deep Brain Stimulation: A Narrative Review},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17010069}
}
EUVIMED